The present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.
Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives
申请人:Binggeli Alfred
公开号:US20080045544A1
公开(公告)日:2008-02-21
This invention is concerned with compounds of the formula
and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
[EN] 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOISOQUINOLÉINE SUBSTITUÉS EN POSITION 4
申请人:PURDUE RESEARCH FOUNDATION
公开号:WO2018035072A1
公开(公告)日:2018-02-22
[00397] This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
申请人:AMGEN INC.
公开号:US20180177767A1
公开(公告)日:2018-06-28
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
[EN] TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF<br/>[FR] ANTAGONISTES SPÉCIFIQUES DU RÉCEPTEUR DE TYPE TOLL 8 ET PROCÉDÉS DE PRODUCTION ET D'UTILISATION ASSOCIÉS
申请人:UNIV COLORADO REGENTS
公开号:WO2019089648A1
公开(公告)日:2019-05-09
Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.